IMARC Group has recently released a new research study titled “Mexico Weight Management Market Size, Share, Trends and Forecast by Diet, Service, Equipment, and Region, 2025-2033”, offers a detailed analysis of the market drivers, segmentation, growth opportunities, trends and competitive landscape to understand the current and future market scenarios.

Market Overview

The Mexico weight management market reached USD 6.75 Billion in 2024 and is expected to grow to USD 11.87 Billion by 2033, with a CAGR of 5.80% during the forecast period of 2025-2033. Key factors driving this growth include rising obesity rates, increasing awareness about lifestyle diseases, and growing health consciousness among younger demographics. Additionally, expanded access to weight-loss medications such as Mounjaro and the influence of fitness apps and social media promote personalized fitness and nutrition approaches.

Study Assumption Years

●     Base Year: 2024

●     Historical Year/Period: 2019-2024

●     Forecast Year/Period: 2025-2033

Mexico Weight Management Market Key Takeaways

●     Market Size in 2024: USD 6.75 Billion

●     CAGR (2025-2033): 5.80%

●     Forecast Period: 2025-2033

●     Mexico is the second most obese country among OECD member economies, with 32.4% of its population aged over 15 classified as obese.

●     The rise in obesity is driven by unhealthy eating habits, low physical activity, and preference for calorie-rich foods.

●     Government initiatives target lifestyle diseases like type 2 diabetes and cardiovascular conditions linked to obesity.

●     Millennials and Gen Z's adoption of wellness culture is creating demand for fitness apps, wearable tech, organic meals, and boutique gyms.

●     Rising digital wellness trends and social media influence are catalyzing personalized fitness and nutrition approaches.

Sample Request Link: https://www.imarcgroup.com/mexico-weight-management-market/requestsample

Market Growth Factors

The Mexico weight management market growth because its obese population and related diseases grow rapidly. The Organization for Economic Co-operation and Development (OECD) says Mexico has obesity at the second-highest levels in the 35 member organization. Obese Mexicans over age 15 are 32.4% of the population, with the United States highest at 38.2%. Unhealthy diets that contain too many energy-dense foods mainly cause the obesity epidemic, and not doing enough physical activity and cultural preferences that favor energy-dense foods also cause it. Urban areas grew. Fast-food outlets and convenience foods increased, not home-cooked meals. This has resulted because of an epidemic of lifestyle diseases including type 2 diabetes, cardiovascular diseases, metabolic syndrome and other diseases associated with obesity.

Another important growth factor is the increasing health and wellness trend of Millennials and Generation Z. The focus has shifted from losing weight to improving people's well-being. This covers physical fitness and mental health. It also covers adopting a healthy lifestyle. Social media influencers and global health and fitness industries like body positivity, veganism, intermittent fasting, and fitness programs have, in turn, directly inspired this generation of young Mexicans, which led to demand for personalized health and fitness products and services, for example fitness apps, wearable technology, organic meal delivery, and boutique fitness memberships.

Wider adoption of obesity drugs like Mounjaro is also expected to contribute to this growth. Eli Lilly has announced Mounjaro's availability in Mexico in the second half of 2025. Biocon has signed a semi-exclusive agreement with Medix, Mexico to provide a low-cost alternative to obesity treatment, Liraglutide (gSaxenda), to a broader range of patients in Mexico. Meanwhile, government campaigns to promote better diet and exercise to combat lifestyle-related diseases (Mexico has a particularly high degree of diabetes prevalence) are expected to drive strong market growth through 2033.

To get more information on this market Request Sample

Market Segmentation

Diet Insights:

●     Functional Beverages: Drinks that provide specific health benefits beyond basic nutrition, catering to weight management needs.

●     Functional Food: Foods fortified or designed to offer health benefits aiding weight regulation and overall wellness.

●     Dietary Supplements: Products containing nutrients or bioactive ingredients to support weight management and metabolic health.

Service Insights:

●     Health Clubs: Facilities offering fitness and wellness services to support weight control and healthy lifestyle.

●     Consultation Services: Professional guidance and counseling on weight loss strategies and health management.

●     Online Weight Loss Services: Digital platforms providing virtual coaching, programs, and resources for weight management.

Equipment Insights:

●     Fitness Equipment:

●     Cardiovascular Training Equipment: Devices designed to improve heart and lung health through aerobic exercise.

●     Strength Training Equipment: Tools and machines aimed at muscle building and strength enhancement.

●     Others: Additional fitness apparatuses supporting diverse exercise routines.

●     Surgical Equipment:

●     Minimally Invasive/Bariatric Equipment: Medical devices used in less invasive weight-loss surgical procedures.

●     Non-Invasive Surgical Equipment: Devices employed in weight management treatments that do not require surgery.

Speak to An Analyst: https://www.imarcgroup.com/request?type=report&id=35287&flag=C

Regional Insights

The report identifies Northern Mexico, Central Mexico, Southern Mexico, and others as key regional markets. However, specific regional statistics such as market shares or CAGR are not provided in the source. The regional segmentation allows for a focused analysis of market dynamics across these geographic areas.

Recent Developments & News

In March 2025, Eli Lilly announced the planned launch of its diabetes and weight loss drug, Mounjaro, in Mexico along with India, Brazil, and China targeting about 900 million potential patients. This move is expected to boost the weight management market by improving access to advanced treatments and enhancing healthcare infrastructure. In May 2024, Biocon entered a semi-exclusive agreement with Mexico-based Medix to distribute and commercialize Liraglutide (gSaxenda), aimed at providing affordable obesity treatment in Mexico. Biocon will manage regulatory approvals and manufacturing, while Medix will handle commercialization locally.

About Us

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us

IMARC Group,

134 N 4th St. Brooklyn, NY 11249, USA,

Email: sales@imarcgroup.com,

Tel No: (D) +91 120 433 0800,

United States: +1-201971-6302